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Patients with vitiligo have been found to have circulating 
antibodies to pigment cells. To evaluate the functional activ-
ity of these antibodies, a highly sensitive europium release 
assay was used to compare complement-mediated cytolysis of 
human melanocytes by sera of 56 patients with vitiligo (20 
with active disease, 25 with inactive disease, 11 with uniden-
tified disease activity) and 47 control individuals. Significant 
melanocyte lysis was mediated by 32 (57%) of the patients 
with vitiligo but by only three (6%) of the control sera (p < 
0.001), and by 17 (85%) of20 patients with active vitiligo 
versus 11 (44%) of 25 patients with inactive disease (p < 
0.025). Mean melanocyte lysis by vitiligo sera was 24% 
versus 6% by control sera (p < 0.0001). A subset of 12 viti-
V itiligo is a skin disorder in which melanocytes are selectively destroyed. Though the cause of melano-cyte damage in vitiligo is not known it is suspected to result from an autoimmune process. The most direct evidence to support this hypothesis is that the major-
ity of patients with vitiligo have circulating antibodies to pigment 
cells [1 - 7]. These antibodies are uncommon in normal individual 
or patients with unrelated skin diseases. The presence and level of 
"vitiligo" a.ntibodies correlates to the extent and activity of vitiligo 
[5,6], suggesting they may be involved in the pathogenesis of the 
disease. However, little is known about the ability of "vitiligo" 
antibodies to actually damage melanocytes. 
In this study, we used a new sensitive europium release assay [8] to 
investigate whether "vitiligo" antibodies have the functional ability 
to kill human melanocytes by complement mediated cytotoxicity. 
MATERIALS AND METHODS 
Sera Sera were obtained from 56 patients with vitiligo (20 with 
active and 25 with inactive disease; disease activity was unknown in 
11 patients), 25 normal individuals and 22 individuals with unre-
lated skin diseases. Active vitiligo was defined as development of 
new lesions or extension of old lesions in the three months preced-
ing collection of sera. This classification was made irrespective of 
therapy or spontaneous repigmentation of some lesions. Extent of 
disease was estimated from percent of body surface area involved. 
This assessment was provided by physicians treating the patients. 
Sera were heat inactivated for 1 h at 56 0 C prior to use. 
Cells Human melanocytes were obtained and grown as previ-
ously described [9]. The melanocytes were long-term cultures dem-
onstrated to be completely free of contaminating fibroblasts and 
Manuscript received February 26, 1992; accepted for publication January 
21, 1993. 
Reprint requests to: Dr. Jean-Claude Bystryn, NYU School of Medicine, 
560 First Avenue, New York, NY 10016. 
ligo sera with high titers of cytolytic antibodies to melano-
cytes (34% mean cytolysis) reacted minimally « 2% mean 
cytolysis) to a panel of control cells that included human and 
murine melanomas, human fibroblasts, lung carcinoma, and 
rhabdomyosarcoma. 
These findings indicate that antibodies present in patients 
with vitiligo have the functional ability to selectively kill 
melanocytes and are more common in active disease. These 
observations support, but do not prove, the hypothesis that 
vitiligo is an autoimmune disease and that antipigment cell 
antibodies have a role in inducing the disease.] Invest Dermatol 
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keratinocytes. Cells were maintained, and experiments were per-
formed in Eagle's minimal essential medium (Mediatech, Washing-
ton, DC) supplemented with 10 ng/ml phorbol myristate acetate 
(PMA) (Sigma, St. Louis, MO), 10- 8 M cholera toxin (LBL, Camp-
bell, CAl, 8% fetal calf serum (GIBCO, Grand Island, NY), 2 mM 
L-glutamine (GIBCO), 0.01 mM non-essential amino acids 
(GIBCO), 100 u/ml penicillin, 100 ug/ml streptomycin, and 0.25 
mg/ml amphotericin B. M20 and M14 human melanoma were 
provided by Dr. Donald Morton (UCLA, Los Angeles, CAl. 
Human melanoma SK-mel-28, SK-mel-23, murine B16 mela-
noma, fibroblasts (CCD-27), lung carcinoma (A549), and rhabdo-
myosarcoma (RD) were obtained from the American Type Culture 
Collection (Rockville, MD). All control cells were cultured in 
EMEM containing PMA and cholera toxin for two subcultures prior 
to use. 
Labeling of Cells with Europium Target cells were labeled as 
described [8,10,11] . Cells were washed twice with 50 ml buffer I 
(pH 7.4) consisting of 50 mM Hepes, 93 mM NaCl, 5 mM KCl, 
and 2 mM MgCl2 and then suspended at 5 X 106 cells/ml in label-
ing buffer (buffer I supplemented with 200 J.lM EuClJ [Fluka, Ron-
konkoma, NY], 1.0 mM diethylenetriaminopentaacetate [Sigma, 
St. Louis] and 500 J.lg/ml dextran sulfate [MW 500,000, Pharmacia 
Fine Chemicals, Piscataway, NJ]) . After incubation at room temper-
ature for 15 min with occasional shaking, the labeling reaction was 
stopped by the addition of 4 J.lljml of 1 M CaCl2 solution. After 
5 min the cells were washed twice with 50 ml buffer III (buffer I 
supplemented with 2 mM CaCl2 and 10 mM glucose) and twice 
with 50 ml MEME medium, and resuspended in MEME medium at 
a concentration of 105 live cells/ml. 
Complement-Mediated Cytotoxicity This was assayed as re-
cently described [8]. For assay, 50 J.ll of europium-labeled cells 
(5000/well) and 50 J.ll of 1: 5 test sera were added to wells of round-
bottomed 96-well microtiter tissue culture plates (Flow laborato-
ries, McLean, VA) and shaken in an icebath for 45 min. Then 100 III 
of 1 : 5 diluted human complement serum (Sigma, St. Louis, MO) 
0022-202X/93/S06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. 
812 
( OL. 100, NO. 6 JUNE 1993 







• * ••• ** 00 
2 0 -- ----........ -. -- -- ----- --- --- --Obl)" ----- - 95% confide nt limit 
•• *.* 0 
*::: -L 8!gg 
OL-__________ ~· ________ _.~~oijoo~~--------------_ 
VITIL IGO CONTROL 
Figure 1. Incidence and level of cytolytic antibodies to melanocytes in 
vitiligo . Fifty-six patients with vitiligo and 47 control individuals were 
jlleasured by complement-mediated cytotoxicity using a europium-release 
~say. Dotted litle, 95% confidenc~ limit. Error 'bars, one SD from means. 
was added to each well and incubated at 37°C. After 2 h, the cells 
were sedimented by centrifugation at 100 X g for 5 min. Twenty 
microliters of supernatant from each well was transferred to flat-
bottomed microtiter strips (Flow laboratories, McLean, VA) con-
taining 200 J1l of enhancement solution consisting of 0.1 % (v Iv) 
Triton X-I00, 15 J1M 2-naphthoyltrifluoroacetone and 50 J1M 
Tri-n-octylphosphine oxide (WalIac, Turku, Finland). After mix-
ing for 5 min, the amount of europium in the supernatant was 
measured in a time-resolved fluorometer (Arcus 1230, LKB-Wal-
lac, Turku, Finland) . All assays were performed in triplicate. Varia-
bility between replicate is usually less than 6% [8]. The cytolysis was 
calculated from the following equation: 
% specific lysis 
experimental release - spontaneous release 
. X 100. 
maximum release - spontaneous release 
Spontaneous release was the amount of europium released by target 
cells incubated with complement only, which is associated with a 
somew-hat higher spontaneous release than serum-only controls, 
but in all cases is less than 9%. Maximum release was the total 
amount of europium released from target cells lysed with 0.1 % 
Triton X-lOO (Sigma, St. Louis, MO). 
Sera -whose cytolytic values exceeded the 95% confidence limit of 
control (mean cytolysis of control sera ± 2SD) were considered 
positive for cytolytic antibodies. Significance of differences 
between or among the groups was compared by a contingency 
table (X2). 
RESULTS 
Incidence and Level of Cytolytic Antibodies to Melano-
cytes Thirty-two of 56 (57%) patients with vitiligo had cytolytic 
antibodies to melanocytes versus three of 47 (6%) control sera (p < 
O.OOl~ (Fig 1 ~nd ~a?le I). Mean melanocyte cytolysis (Mean ± SD) 
in patients with vitiligo was 24 ± 12% versus 6 ± 7% in control 
individuals (p < 0.001). There is no difference between normal 
Table I. Incidence of Cytolytic Antibodies in Vitiligo 
Number of Number (%) 
Diagnosis Patients Positive' 
Vitiligo 56 32 (57%)1 
Control 47 3 (6%) 
• Percent lysis of melanocytes 2: (mean ± 2 SO) of controls. 




24 ± 12 (2-55) 
6 ± 7 (0-26) 
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Table II. Incidence of Cytolytic Antibodies in Active and 
Inactive Vitiligo 
Number of Number (%) % Cytolysis 
Activiry Patients Positive' (Mean±SD) 
Active 20 17 (85%)1 29 ± 12 
Inactive 25 11 (44%) 21 ± 11 
• Percent lysis of melanocytes 2: (mean ± 2 SO) of controls. 
• p versus inactive disease < 0.025. 
individuals (mean 7 ± 9%) and individuals with unrelated skin dis-
eases (mean 4.3 ± 6%). 
~elation Between Disease Activity and Antibody Levels 
The relation between the activity of vitiligo and the presence and 
level of cytolytic antibodies to melanocytes was examined in a sub-
set of 45 patients with vitiligo in whom information on clinical 
activity of disease was available. The results are shown in Table II. 
Cytolytic antibodies were more frequent in patients with active 
v-itiligo (present in 85% of 20 patients) than in those with inactive 
disease (present in 44% of 25 patients) (p < 0.025). The level of 
cytolytic antibodies was somewhat higher in patients with active 
v-itiligo (mean cytolysis of 29 ± 12%) than in those with inactive 
disease (mean cytolysis of 21 ± 11%). 
~elation Between Disease Extent and Antibody Levels The 
association was examined in a subset of 44 patients in whom infor-
mation on the extent of body surface area involved was available. As 
shown in Table III, there is a trend between more extensive involve-
ment and higher frequency and level of cytolytic antibodies, but the 
differences are not statistically significant. 
Specificity of Cytolytic Vitiligo Antibodies To examine the 
specificity of cytolytic antibodies present in patients with vitiligo, a 
subset of 12 vitiligo sera with high titers of cytolytic antibodies to 
melanocytes was tested for cytolytic activity to a panel of control 
cells. The killing of melanocytes by vitiligo sera was selective. Cy-
colytic activity of vitiligo antibodies against melanocytes (mean of 
34 ± 6%) was much higher than against melanoma and non-pig-
ment control cells (0% to SK-mel-28; 2 ± 3% to SK-mel-23; 1 ± 
2% to M14; 0.4 ± 0.9% to M20; 2 ± 4% to B16; 1 ± 1.6% to 
CCD-27; 0.6 ± 0.8% to A549; and 0.2 ± 0.6% to RD) (Fig 2). 
DISCUSSION 
The results of this study indicate that antibodies in sera of patients 
with vitiligo can selectively kill melanocytes itt vitro by complement 
mediated cytotoxicity and that there is a relation between the activ-
ity of vitiligo and the presence of cytolytic antibodies. 
A number of indirect and direct observations suggest vitiligo may 
be an autoimmune disease to pigment cells. Vitiligo is associated 
with a variety of autoimmune diseases and organ-specific autoanti-
bodies [12]. Most effective treatments that induce repigmentation in 
vitiligo such as ultraviolet light and psoralen [13] , topical hi?h-po-
tency steroids [14,15], and topical cytotoxic drugs [16,17] are Immu-
nosuppressive, suggesting that their benefit could result frOl~ .s~p­
pression oflocal immune reactions damaging melanocytes. Vltlligo 
can be induced in chimpanzees immunized to melanoma cells [18]. 
Table Ill. Relation Between Cytolytic Antibodies 
and Extent of Vitiligo 
Disease Number of Number (%) % Cytolysis 
Extent Patients Positive' (Mean ± SD) P 
:5:1% 12 5 (42%) 20 ± 11 
1-5% 16 13 (81%) 27 ± 12 > 0.05 
>5% 16 10 (63%) 27 ± 12 
• Percent lysis of melanocytes 2: (mea n ± 2 SO) of controls. 
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Figure 2. Specificity of cytolytic vitiligo antibodies. To examine the speci-
ficity of cytolytic antibodies present in patients with vitiligo, 12 vitiligo sera 
with high titers of cytolytic antibodies to melanocyte were tested for cytoly-
tic activity against human melanoma cells (SK-mel-28, SK-mel-23, M14, 
M20), murine B16 melanomll, human fibroblasts (CCD-27), lung carci-
noma (A549), and rhabdomyosarcoma (RD). Error bars, one SD from the 
means. 
Sinclair swine in whom melanoma regresses spontaneously develop 
vitiligo (19). These swine develop antibodies to melanoma cells; the 
frequency and level of these antimelanoma antibodies correlates 
with the appearance of vitiligo and the regression of melanoma,t 
suggesting that immune reactions to malignant pigment cells may 
destroy normal pigment cells. More directly, antibodies to melano-
cytes are often present in patients with common vitiligo, but are 
uncommon in individuals with non-pigmentary skin diseases or in 
normal persons [1,2,7,20). Immunofluorescence and immunopre-
cipitation studies indicated these antibodies are directed to cell sur-
face antigens [1,2,7). The incidence and level of these antibodies 
parallels the extent of pigment cell destruction (5) and the activity of 
the disease (6), and may be inversely related to the effect of therapy 
(20). Similar antibodies have also been found in some animals with 
vitiligo [21]. These observations suggest that vitiligo antibodies are 
involved in the pathogenesis of the disease. This possibility is sup-
ported by the observations of Norris et at [22] that vitiligo antibodies 
can damage human melanocytes in vitro. They found that four 
(40%) of 10 vitiligo sera could kill melanocytes by complement-
mediated cytotoxicity and eight (80%) by antibody-dependent cel-
lular cytotoxicity. Similar activity was found in only 0% and 10%, 
respectively, ofl0 control sera. By contrast, cellular immune mecha-
nism appears to play only a minor role in the pathogenesis of vitiligo 
as only a sparse inflammatory cell infiltrate is present in active lesion 
of the disease (23). 
In this study we have used a new and very sensitive assay to 
measure antibody-dependent complement-mediated killing of mel-
anocytes in which cell damage is measured by release of europium 
instead of by conventional trypan blue exclusion or StCr release. 
The europium release assay is a simple, quantitative method to mea-
sure complement-mediated cytolysis that is more sensitive and rapid 
than conventional assays (8) . The results of this study involving 56 
patients with vitiligo ~onfirm. in a larger gro?P th.at the majority 
(57%) of individuals With VItiligo have cytolytiC antibodies to mel a-
nocytes that can be detected by complement-dep~ndent cytotoxic-
ity. Similar antibodies were present 111 only 6% of 47 control sera. 
These cytolytic antibodies were much more frequent in patients 
with active vitiligo (85%) than in those with inactive disease (44%) 
t Cui], e/ al: Antimelanoma 'antibodies in swine with spontaneously 
regressing melanoma (abstr 2094). ProcAm Assoc Cancer Res 33:351,1992. 
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and their level was also higher (mean cytolysis of 29 ± 12%) in 
active disease versus 21 ± 11 % in inactive disease. These differences 
are statistically significant. We suspect, but have not proved, that 
antimelanocyte antibodies discussed in this study are, at least in part, 
similar to previously described "vitiligo" antibodies to melanocyte 
surface antigens [1,2,7,21). 
The killing of melanocytes by "vitiligo" cytolytic antibodies is 
selective. The cytolytic activity of "vitiligo" antibodies against mel-
anocytes (mean cytolysis of34 ± 6%) was much higher than against 
melanoma or non-pigment control cells (in all cases less than 2%). 
Whether the selective killing of melanocytes is because "vitiligo" 
antibodies are directed to specific melanocyte antigens or because 
melanocytes are more susceptible to immune injury than other cells 
is not known. There are observations that support both possibilities. 
We have observed that some "vitiligo" antibodies are directed in 
part to antigens preferentially expressed on melanocytes, which 
supports the first possibility [7]. However, other "vitiligo" antibod-
ies are directed to antigens shared by melanocytes and other control 
cells. This resul t, as well as the prior studies that indicate that mela-
nocytes are more sensitive to immune damage than other cells [24] , 
support the second possibility. 
These results support the growing body of direct and indirect 
observations that suggest that antipigment antibodies are involved 
in the pathogenesis of vitiligo. The inability to detect such antibod-
ies in some patients with active disease does not preclude that they 
playa role in mediating vitiligo because pathogenic autoantibodies 
are similarly undetectable in some patients with other autoanti-
body-mediated diseases like pemphigus or bullous pemphigoid. 
The reason that antibodies are not detectable in some patients is not 
known. Possibilities include insufficient sensitivity of the test, and 
the blocking of antibodies by circulating antigens or anti-idiotype 
antibodies. We have not excluded the possibility that the antipig-
ment antibodies result from rather than cause, the destruction of 
pigment cell that occurs in vitiligo. 
In summary, the results of this study indicate that most patients 
with vitiligo have pigment cell antibodies that have the functional 
capability to selectively kill melanocytes and that these antibodies 
are more common in patients with active disease. These observa-
tions support, but not prove, the hypothesis that vitiligo is an au-
toimmune disease and it is mediated in part by antipigment cell 
antibodies. 
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